Brokerages Anticipate Danaher Corporation (DHR) to Post $0.95 EPS

Wall Street brokerages expect Danaher Corporation (NYSE:DHR) to announce $0.95 earnings per share (EPS) for the current fiscal quarter, according to Zacks. Seven analysts have issued estimates for Danaher Corporation’s earnings. The lowest EPS estimate is $0.93 and the highest is $0.96. Danaher Corporation posted earnings per share of $0.87 during the same quarter last year, which would suggest a positive year over year growth rate of 9.2%. The firm is expected to report its next quarterly earnings report on Thursday, October 19th.

On average, analysts expect that Danaher Corporation will report full-year earnings of $3.94 per share for the current fiscal year, with EPS estimates ranging from $3.90 to $3.96. For the next year, analysts expect that the company will post earnings of $4.27 per share, with EPS estimates ranging from $4.20 to $4.35. Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that follow Danaher Corporation.

Danaher Corporation (NYSE:DHR) last announced its quarterly earnings results on Thursday, July 20th. The conglomerate reported $0.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.97 by $0.02. Danaher Corporation had a return on equity of 11.29% and a net margin of 12.63%. The firm had revenue of $4.51 billion during the quarter, compared to the consensus estimate of $4.50 billion. During the same period in the prior year, the firm earned $0.90 EPS. The firm’s quarterly revenue was up 6.3% compared to the same quarter last year.

Several research firms recently issued reports on DHR. Wells Fargo & Company began coverage on shares of Danaher Corporation in a research note on Thursday, July 13th. They issued a “market perform” rating and a $90.00 price objective for the company. BidaskClub raised shares of Danaher Corporation from a “sell” rating to a “hold” rating in a research note on Wednesday. Citigroup Inc. reaffirmed a “buy” rating and issued a $96.00 price objective (down previously from $98.00) on shares of Danaher Corporation in a research note on Friday. Zacks Investment Research lowered shares of Danaher Corporation from a “hold” rating to a “sell” rating in a research note on Wednesday, July 12th. Finally, Royal Bank Of Canada reaffirmed a “hold” rating and issued a $88.00 price objective on shares of Danaher Corporation in a research note on Wednesday, July 12th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $91.98.

COPYRIGHT VIOLATION WARNING: This news story was first reported by [[site]] and is owned by of [[site]]. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at [[permalink]].

Shares of Danaher Corporation (NYSE:DHR) traded down 0.18% during mid-day trading on Monday, reaching $83.05. The company had a trading volume of 3,606,106 shares. The company’s 50-day moving average is $84.75 and its 200 day moving average is $84.18. The stock has a market capitalization of $57.65 billion, a P/E ratio of 25.31 and a beta of 1.05. Danaher Corporation has a 52-week low of $75.71 and a 52-week high of $88.01.

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 28th. Investors of record on Friday, June 30th will be paid a $0.14 dividend. The ex-dividend date of this dividend is Wednesday, June 28th. This represents a $0.56 dividend on an annualized basis and a yield of 0.67%. Danaher Corporation’s payout ratio is currently 17.83%.

In related news, EVP William K. Daniel sold 17,444 shares of the company’s stock in a transaction dated Tuesday, April 25th. The shares were sold at an average price of $83.07, for a total value of $1,449,073.08. Following the sale, the executive vice president now owns 132,995 shares of the company’s stock, valued at $11,047,894.65. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Angela S. Lalor sold 10,815 shares of the company’s stock in a transaction dated Tuesday, May 23rd. The shares were sold at an average price of $84.16, for a total transaction of $910,190.40. Following the completion of the sale, the senior vice president now directly owns 39,020 shares in the company, valued at approximately $3,283,923.20. The disclosure for this sale can be found here. Insiders own 12.20% of the company’s stock.

A number of hedge funds have recently bought and sold shares of DHR. Rosenbaum Jay D. boosted its stake in Danaher Corporation by 10.1% in the second quarter. Rosenbaum Jay D. now owns 4,400 shares of the conglomerate’s stock worth $371,000 after buying an additional 405 shares during the last quarter. Cohen Lawrence B boosted its stake in Danaher Corporation by 10.1% in the second quarter. Cohen Lawrence B now owns 3,490 shares of the conglomerate’s stock worth $295,000 after buying an additional 320 shares during the last quarter. Quantitative Systematic Strategies LLC acquired a new stake in Danaher Corporation during the second quarter worth $645,000. Duncker Streett & Co. Inc. boosted its stake in Danaher Corporation by 2.4% in the second quarter. Duncker Streett & Co. Inc. now owns 66,693 shares of the conglomerate’s stock worth $5,628,000 after buying an additional 1,579 shares during the last quarter. Finally, Hermes Investment Management Ltd. acquired a new stake in Danaher Corporation during the second quarter worth $412,000. 76.30% of the stock is currently owned by institutional investors and hedge funds.

Danaher Corporation Company Profile

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Get a free copy of the Zacks research report on Danaher Corporation (DHR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com